Comparative Pharmacology
Head-to-head clinical analysis: ISOVUE 200 versus ISOVUE M 200.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ISOVUE 200 versus ISOVUE M 200.
ISOVUE-200 vs ISOVUE-M 200
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Iodinated contrast medium that attenuates X-rays, providing radiographic contrast by increasing the density of blood vessels and tissues.
Iodinated radiocontrast agent that attenuates X-rays, allowing visualization of vascular structures and organs during imaging procedures.
Intravenous administration of 1.0-2.0 mL/kg (200 mg iodine/mL) for computed tomography; intra-arterial doses vary by procedure, typically 5-80 mL total. Maximum recommended dose: 2.0 mL/kg.
Intrathecal: 8-12 mL (200 mg Iodine/mL) for lumbar myelography. Intravenous: 50-200 mL for contrast enhancement, administered as a bolus or infusion per procedure.
None Documented
None Documented
2 hours in normal renal function; prolongs up to 30 hours in severe renal impairment. Closely correlates with creatinine clearance.
Terminal elimination half-life is approximately 1.5–2 hours in patients with normal renal function. Prolonged in renal impairment, which may necessitate dose adjustment.
Renal: 100% unchanged as iohexol; glomerular filtration with no tubular reabsorption. No biliary/fecal elimination.
Primarily renal: >90% of the administered dose is excreted unchanged in urine within 24 hours. Less than 1% is excreted via biliary/fecal routes.
Category C
Category C
Contrast Media
Contrast Media